Jade Biosciences

Today we reported third quarter 2025 financial results and key company updates. We continued to make meaningful progress toward our mission of delivering potentially best-in-class therapies for autoimmune diseases. Key quarter highlights include:     ✅ Presented new preclinical safety and translational data at #ASN2025 that further support our lead program JADE101’s potential to be a best-in-class anti-APRIL therapy  ✅ Initiated a Phase 1 trial for JADE101 ✅ Introduced our second development candidate, JADE201, which builds on validated BAFF-R biology to potentially address a broad range of autoimmune diseases ✅ Completed a $135 million private financing     Read the full update here: https://lnkd.in/ggdhbsmm    #AutoimmuneDiseases #JBIO 

We’re pleased to share new preclinical safety results for JADE101, our investigational anti-APRIL monoclonal antibody for IgA nephropathy, and a translational analysis of APRIL mediated biomarker responses, at the American Society of Nephrology Kidney Week. JADE101 is currently being evaluated in a Phase 1 healthy volunteer study, with interim data expected in the first half of 2026 that is anticipated to define the dose and dose interval selection for study in patient trials. Read more: https://lnkd.in/gcUDn-yS   #ASN2025 #IgAN #AutoimmuneDiseases 

Jade will be participating in several healthcare and biotech investor conferences this November, including a fireside chat at the Wedbush Rewind ASN event, and company presentations at the Stifel Healthcare Conference, TD Cowen I&I virtual summit and at the Jefferies Global Healthcare Conference. Register here: https://lnkd.in/gx7d4qZh   #JBIO #AutoimmuneDiseases 

Jade is headed to #ASN2025 #KidneyWeek where we’ll present new preclinical safety and translational data for JADE101, our lead investigational candidate for the treatment of immunoglobulin A nephropathy. Learn more: https://lnkd.in/g2UnDJWW   #Nephrology, #KidneyHealth, #KidneyCare, #MedicalConference 

Today, we introduced JADE201, our second development candidate — a monoclonal antibody designed to target BAFF-R. Together with JADE101, our anti-APRIL antibody now in Phase 1, JADE201 expands our efforts to address autoimmune diseases through distinct but complementary pathways. We also announced the closing of a new financing of $135M that strengthens our ability to advance our mission. You can read more in the press releases below and join us on this morning’s conference call and webcast at 8:00 a.m. ET.  https://lnkd.in/gyhrEYn4 https://lnkd.in/gR3-hv3s

Jade Biosciences CEO Tom Frohlich will join industry peers as part of the panel “Immunology: Creating the Next Blockbuster in I&I” at this year’s World Medical Innovation Forum, hosted by Bank of America and Mass General Brigham.    Learn more: https://lnkd.in/gcWd8Qvh     #WMIF2025 

We’ve reached an important milestone — Jade’s first clinical trial is now underway for our lead candidate JADE101.    JADE101 is an investigational monoclonal antibody designed to selectively inhibit the activity of APRIL for the treatment of IgA nephropathy or IgAN.    This Phase 1 study in healthy adult volunteers marks Jade’s transition to a clinical-stage company and represents a meaningful step toward our goal to deliver differentiated therapies for people living with autoimmune diseases.    Read the full announcement: https://lnkd.in/gTsYgkhg   #JBIO #IgAN #Autoimmune 

September will be an exciting month for Jade as we take part in three leading healthcare forums: - Cantor Global Healthcare Conference  - Stifel Virtual Immunology & Inflammation Forum  - World Medical Innovation Forum (hosted by Bank of America and Mass General Brigham) Company leaders will be engaging in fireside chats, joining a panel on the future of immunology, and meeting with investors to share Jade’s story. Get the details here: https://lnkd.in/gx7d4qZh   #JBIO 

The Jade team has had a productive second quarter, marking key milestones in our progress toward developing potentially best-in-class therapies for autoimmune diseases. We completed a reverse merger, closed a significant financing, and began trading on Nasdaq under JBIO. We also shared new preclinical data for JADE101 in IgA nephropathy at the recent European Renal Association Congress and are looking forward to starting a Phase 1 trial of JADE101 in healthy volunteers in the third quarter.     Read the full update here: https://lnkd.in/g8z5K_MP #biotech #autoimmune #IgAN #APRIL #clinicaldevelopment #JBIO 

We’re headed to two upcoming investor conferences. Our CEO Tom Frohlich and CSO and Head of R&D Andrew King will take part in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14 and at the Stifel Biotech Summer Summit on August 13. Read more: https://lnkd.in/gCAYHVca